You are here: Industry Insights > Insulin

News List

Biocon gets European nod for its insulin to market globally biospectrumasia
March 29, 2018
Biocon and Mylan received approval from the European Commission and the Australian regulatory body for marketing biosimilar insulin glargine globally
Mylan and Biocon Receive Approvals from the European Commission and TGA Australia for Semglee™, Biosimilar Insulin Glargine biospace
March 29, 2018
Semglee™ 100 units/mL 3 mL prefilled disposable pen for people with diabetes, is the first biosimilar from Biocon and Mylan's joint portfolio to be approved in Europe.
FDA approves Admelog, the first follow-on insulin product to treat diabetes europeanpharmaceuticalreview
December 13, 2017
The FDA has approved Admelog, a short-acting insulin indicated to improve control in blood sugar levels in diabetes…
Towards a smarter insulin pharmaceutical-journal
November 13, 2017
Scientists aim to make a once-a-day type of insulin that would become active only in the presence of high glucose concentrations.
Eli Lilly announces an investment of US$72 million in core business pharmaasia
November 01, 2017
The company has a nine decade legacy of researching and producing the drug.
FDA approves new insulin Fiasp® by Novo Nordisk pharmaasia
October 09, 2017
New fast-acting mealtime insulin Fiasp® by Novo Nordisk has been approved by the FDA for both type 1 and type 2 diabetes in adult patients.
Novo's Xultophy beats basal insulin in cutting cardiovascular risk Published on 14/09/17 at 09:49am pharmafile
September 15, 2017
Novo Nordisk has unveiled new data on its diabetes treatment Xultophy (insulin degludec/liraglutide) which supports its efficacy in reducing risk factors associated with an increased risk of developing cardiovascular disease.
Japanese researchers develop a long-lasting insulin analog biospectrumasia
August 25, 2017
The researchers demonstrated that selenoinsulin analog had a nearly identical structure to that of bovine pancreatic insulin, suggesting that they have similar bioactivity.
Testing the safety of immunotherapy in diabetes fiercebiotech
August 10, 2017
Some researchers hope immunotherapy will make these tools obsolete in treating diabetes.
Green tea ingredient may ameliorate memory impairment, brain insulin resistance, and obesity worldpharmanews
July 31, 2017
the most abundant catechin and biologically active component in green tea, could alleviate high-fat and high-fructose (HFFD)-induced insulin resistance and cognitive impairment.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page